Expect Equity LLC Purchases New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Expect Equity LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, Holdings Channel.com reports. The firm acquired 24,924 shares of the medical equipment provider’s stock, valued at approximately $2,230,000. Lantheus comprises about 2.3% of Expect Equity LLC’s portfolio, making the stock its 21st biggest position.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after purchasing an additional 3,772 shares during the period. Empirical Asset Management LLC bought a new stake in Lantheus in the fourth quarter worth about $323,000. Focus Financial Network Inc. purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $292,000. Harbor Capital Advisors Inc. grew its stake in shares of Lantheus by 12.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock valued at $13,006,000 after buying an additional 16,466 shares during the last quarter. Finally, World Investment Advisors LLC purchased a new stake in shares of Lantheus in the third quarter worth approximately $60,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 0.4 %

Shares of Lantheus stock opened at $80.16 on Friday. The stock’s fifty day moving average price is $99.90 and its 200-day moving average price is $94.57. The firm has a market cap of $5.49 billion, a P/E ratio of 13.34 and a beta of 0.23. Lantheus Holdings, Inc. has a 12 month low of $74.34 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analysts’ expectations of $377.37 million. During the same period last year, the business posted $1.69 EPS. The company’s revenue for the quarter was up .8% on a year-over-year basis. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research note on Thursday. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $132.67.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 over the last 90 days. Company insiders own 2.00% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.